- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 14,629,786
- Total 13F shares
- 8,978,370
- Share change
- -427,571
- Total reported value
- $13,355,302
- Price per share
- $1.49
- Number of holders
- 59
- Value change
- -$657,201
- Number of buys
- 21
- Number of sells
- 39
Quarterly Holders Quick Answers
What is CUSIP 746964105?
CUSIP 746964105 identifies QTTB - Q32 Bio Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 746964105:
Top shareholders of QTTB - Q32 Bio Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
3/4/5
|
Company · Director, 10%+ Owner |
15%
|
2,252,987
|
$3,717,429 | — | 31 Mar 2025 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
14%
|
2,092,106
|
$3,451,975 | — | 31 Mar 2025 | |
| W. Bradford Smith |
3/4/5
|
Chief Financial and Business Officer and Treasurer |
—
mixed-class rows
|
249,000
mixed-class rows
|
$2,899,867 | — | 23 Feb 2023 | |
| Carlyle Group Inc. |
13F
|
Company |
7.5%
|
1,102,741
|
$1,808,495 | — | 31 Mar 2025 | |
| Michael L. Blum |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
121,000
mixed-class rows
|
$1,415,233 | — | 23 Feb 2023 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
5.5%
|
803,425
|
$1,325,651 | — | 31 Mar 2025 | |
| Jason Campagna |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
108,187
mixed-class rows
|
$1,221,995 | — | 24 Feb 2025 | |
| Atlas Venture Fund X, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,092,106
|
$1,194,801 | — | 25 Mar 2024 | |
| PFIZER INC |
13D/G
13F
|
Pfizer Inc. (IRS Identification No.: 13-5315170) · Company |
2.3%
|
277,777
|
$994,442 | $0 | 31 Dec 2024 | |
| Monaco Asset Management SAM |
13F
|
Company |
3.5%
|
505,451
|
$833,994 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
3.1%
|
457,371
|
$754,663 | — | 31 Mar 2025 | |
| ARCH Venture Management, LLC |
13F
|
Company |
2.2%
|
320,482
|
$532,000 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.1%
|
309,214
|
$510,204 | — | 31 Mar 2025 | |
| Sanofi |
13F
|
Company |
1.7%
|
244,083
|
$402,737 | — | 31 Mar 2025 | |
| Timothy P. Kelly |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
33,000
mixed-class rows
|
$383,965 | — | 24 Feb 2022 | |
| BRISTOL MYERS SQUIBB CO |
13D/G
|
— |
1.6%
|
200,244
|
$312,381 | $0 | 31 Dec 2024 | |
| Alise Reicin |
3/4/5
|
Director |
—
class O/S missing
|
23,000
|
$308,660 | — | 14 Jun 2023 | |
| Jeffrey V Poulton |
3/4/5
|
Director |
—
class O/S missing
|
23,000
|
$308,660 | — | 14 Jun 2023 | |
| Matthew R. Patterson |
3/4/5
|
Director |
—
class O/S missing
|
23,000
|
$308,660 | — | 14 Jun 2023 | |
| Steven Gillis |
3/4/5
|
Director |
—
class O/S missing
|
23,000
|
$308,660 | — | 14 Jun 2023 | |
| Kush Parmar |
3/4/5
|
Director |
—
class O/S missing
|
18,000
|
$241,560 | — | 15 Jun 2022 | |
| Richard J. Gregory |
3/4/5
|
Director |
—
class O/S missing
|
18,000
|
$241,560 | — | 15 Jun 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.94%
|
137,509
|
$226,949 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.94%
|
137,498
|
$226,872 | — | 31 Mar 2025 | |
| Trustees of Columbia University in the City of New York |
13F
|
Company |
0.92%
|
133,903
|
$220,940 | — | 31 Mar 2025 | |
| Mariner, LLC |
13F
|
Company |
0.58%
|
84,780
|
$139,887 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.43%
|
62,391
|
$102,945 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.41%
|
60,134
|
$99,222 | — | 31 Mar 2025 | |
| Albert Seymour |
3/4/5
|
President and Chief Executive Officer, Director |
—
mixed-class rows
|
160,254
mixed-class rows
|
$96,184 | — | 06 Sep 2023 | |
| Nuveen, LLC |
13F
|
Company |
0.38%
|
55,886
|
$92,212 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.3%
|
44,373
|
$73,216 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.28%
|
41,302
|
$68,148 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.23%
|
33,431
|
$55,161 | — | 31 Mar 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.21%
|
31,138
|
$50,000 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.19%
|
27,777
|
$45,832 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.17%
|
25,018
|
$41,280 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.11%
|
16,192
|
$26,717 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.1%
|
14,657
|
$24,185 | — | 31 Mar 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.1%
|
14,528
|
$23,971 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.1%
|
14,190
|
$23,414 | — | 31 Mar 2025 | |
| Corton Capital Inc. |
13F
|
Company |
0.08%
|
11,607
|
$19,152 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.08%
|
11,156
|
$18,401 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.07%
|
10,810
|
$17,837 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.07%
|
10,746
|
$17,731 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.06%
|
9,170
|
$15,130 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.05%
|
7,292
|
$12,032 | — | 31 Mar 2025 | |
| Gabriel Cohn |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
11,339
mixed-class rows
|
$11,506 | — | 01 Jan 2022 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0.03%
|
5,039
|
$8,314 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.03%
|
4,402
|
$7,264 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.03%
|
3,658
|
$6,036 | — | 31 Mar 2025 |
Institutional Holders of Q32 Bio Inc. - COMMON STOCK (QTTB) as of Q2 2025
As of 30 Jun 2025,
Q32 Bio Inc. - COMMON STOCK (QTTB) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,978,370 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Atlas Venture Life Science Advisors, LLC, Carlyle Group Inc., ACORN CAPITAL ADVISORS, LLC, Monaco Asset Management SAM, ARCH Venture Management, LLC, Pfizer Inc, VANGUARD GROUP INC, Sanofi, and BlackRock, Inc..
This page lists
60
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
71
Q2 2025 holders
59
Holder diff
-12
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.